EFFECTIVENESS OF PERSONALIZED PREVENTION STRATEGY FOR RECURRENT HEMORRHAGIC STROKE IN PRIMARY HEALTHCARE
Keywords:
hemorrhagic stroke, recurrent stroke, prevention, primary healthcare, personalized medicine, risk stratificationAbstract
Objective: To evaluate the effectiveness of a personalized prevention strategy for recurrent hemorrhagic stroke in primary healthcare settings. Materials and methods: A prospective controlled study was conducted involving 240 patients who had suffered a hemorrhagic stroke. The main group (n=120) received personalized prevention based on a developed risk stratification scale, while the control group (n=120) received standard therapy. The follow-up period was 24 months. The primary endpoint was the frequency of recurrent hemorrhagic strokes, and secondary endpoints included mortality, functional outcomes according to the modified Rankin Scale (mRS), and quality of life. Results: In the main group, the frequency of recurrent hemorrhagic strokes was 8.3% versus 18.3% in the control group (RR=0.45; 95% CI: 0.23-0.89; p=0.021). Mortality was significantly lower in the main group (5.8% versus 14.2%; p=0.032). The proportion of patients with functional independence (mRS 0-2) at 24 months was 67.5% in the main group versus 48.3% in the control group (p=0.003). Conclusion: The personalized prevention strategy for recurrent hemorrhagic stroke in primary healthcare demonstrates high effectiveness in reducing recurrence rates, mortality, and improving functional outcomes.
References
Anderson CS, Huang Y, Lindley RI, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (INTERACT3): an open-label, blinded-endpoint, randomised controlled trial. Lancet. 2023;401(10383):1319-1328.
Biffi A, Kuramatsu JB, Leasure A, et al. Oral anticoagulant-related intracerebral hemorrhage. Stroke. 2021;52(1):233-243.
Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714-725.
Feigin VL, Stark BA, Johnson CO, et al. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795-820.
Hostettler IC, Schwarz G, Ambler G, et al. Intracerebral hemorrhage in the Swiss stroke registry (Swiss SOS): predictors of outcome and trends over time. Stroke. 2023;54(2):398-407.
Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. 2022;21(3):261-275.
Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2022;93(4):431-441.
Rodrigues MA, Samarasekera N, Lerpiniere C, et al. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. Lancet Neurol. 2021;20(11):931-940.
Wilson D, Ambler G, Banerjee G, et al. Statistical analysis plan for the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2). Int J Stroke. 2023;18(2):234-241.
Zhang L, Chopp M, Zhang Y, et al. Diabetes mellitus and cerebral amyloid angiopathy: a review. J Neuroinflammation. 2022;19(1):248.
